In 2011, a supercomputer won $1 million on Jeopardy! In 2016, that same supercomputer is tackling a challenge quantified not in millions of dollars but in millions of cancer patients.
The goal is to use Watson’s natural language processing to mine the medical literature and a patient’s records to provide treatment advice. And this month the Watson computer system is drastically expanding its reach—from one hospital in Thailand to six in India and a planned 21 more in China.
Supernus announced that the Food and Drug Administration (FDA) has granted tentative approval to the supplemental New Drug Application (sNDA) proposing a label expansion for Trokendi XR (topiramate) extended-release capsules to include prophylaxis of migraine headache in adults.
Precision Medicine is gathering pace, driven by leaders from across healthcare, academia, Big Pharma, government, technology innovators and more. In the past year the investment of both time and resources into this exciting new area has grown exponentially with exciting projects and initiatives springing up across the globe.
For the first time Phacilitate has gathered all of these influencers and industry innovators together into the Top 50 Big Data Influencers in Precision Medicine eBook.
Chevy Chase venture fund New Enterprise Associates upped its bet on ThreatQuotient, a Reston-based cybersecurity analytics start-up, in a $12 million investment announced Tuesday.
ThreatQuotient operates a set of data analytics tools for corporate cybersecurity analysts, meant to help sort through the millions of data points that might predict the next hack. The company was founded in 2013 by two technologists working out of AOL’s Fishbowl Labs incubator in Sterling, Va., and chief executive John Czupak joined in late 2015.
The company, which employs more than 300 people at its plant in Ulverston, was praised for its work helping tackle diseases in both the western and developing world.
This list appeared in prestigious American publication Fortune, which has its headquarters in New York City.
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine announced today a $14.4 million grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) to tackle a significant scientific global challenge in HIV vaccine research – the inability to produce long-lasting antibodies to protect against HIV infection. The announcement was made today by Robert C. Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor of Medicine, Director, Institute of Human Virology, University of Maryland School of Medicine, and his colleagues George Lewis, PhD, Professor of Microbiology and Immunology, Director Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine and Anthony DeVico, PhD, Professor of Medicine, Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine. IHV’s grant collaborators include Guido Silvestri, MD at the Yerkes National Primate Research Center of Emory University and Warner Greene, MD, PhD, of the Gladstone Institute of Virology & Immunology at the University of California at San Francisco.
The Institute of Human Virology at the University of Maryland School of Medicine received a $14.4 million grant for HIV research.
The grant, awarded by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), will fund research aimed at tackling a significant scientific challenge in HIV vaccine research – the inability to produce long-lasting antibodies to protect against the infection.
New treatments are needed for severe asthmatics who do not respond to standard therapy with inhaled steroids, especially those with a “type 2 low” phenotype, such as individuals with neutrophil-predominant inflammation. This solicitation is for the development and early commercialization of an inhalational formulation of the 5A apolipoprotein A-I (apoA-I) mimetic peptide that can be administered to asthmatic subjects in Phase I clinical trials and subsequently developed into a new treatment for severe asthma.
Proposals will be due October 21, 5 pm and there will be a pre-proposal webinar on August 24, 2 pm (http://bit.ly/FY17ContractsWebinar) for companies who may be interested in applying.”
This free event brought to you by BioHealth Innovation is to gather interested small businesses seeking funding from the NCI SBIR grants program.
When: Wednesday, September 7, 2016 3:00 PM – 4:30 PM
Where:Germantown Innovation Center 27201 Goldenrod Lane Germantown, MD 20876
RSVP: jorozco@scheerpartners.com
Attendance is limitied to BioHealth companies. The parking at the GIC can handle 20 non-resident companies labeled in the GIC reserve spaces. Others will be ticketed.
More and more people agree: cybersecurity is in our region’s DNA and can continue to be a boom for greater Washington.
But venture capital is pivotal in providing the accelerant for rapid growth of technology companies, and it I fear that the lack of sufficient risk capital is strangling some promising startups.
